|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV045265739 |
| 003 |
DE-627 |
| 005 |
20230624114321.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
190205s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.pcd.2018.09.003
|2 doi
|
| 028 |
5 |
2 |
|a GBV00000000000464.pica
|
| 035 |
|
|
|a (DE-627)ELV045265739
|
| 035 |
|
|
|a (ELSEVIER)S1751-9918(18)30192-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 630
|q VZ
|
| 082 |
0 |
4 |
|a 640
|q VZ
|
| 082 |
0 |
4 |
|a 590
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 600
|q VZ
|
| 084 |
|
|
|a 50.70
|2 bkl
|
| 100 |
1 |
|
|a Rachdi, Chaima
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients
|
| 264 |
|
1 |
|c 2019
|
| 300 |
|
|
|a 6
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a • Sertraline improved anthropometrics variables in depressed type 2 diabetic patients. • At week 12, sertraline 50mg produced 2.5% loss in body weight from baseline. • Depressive patients under sertraline lost on average seven centimeters in waist circumference. • Sertraline was effective and safe in depressive diabetic type 2 patients.
|
| 650 |
|
7 |
|a Glycemic control
|2 Elsevier
|
| 650 |
|
7 |
|a Body mass index
|2 Elsevier
|
| 650 |
|
7 |
|a Depression
|2 Elsevier
|
| 650 |
|
7 |
|a Type 2 diabetes mellitus
|2 Elsevier
|
| 650 |
|
7 |
|a Sertraline
|2 Elsevier
|
| 700 |
1 |
|
|a Damak, Rahma
|4 oth
|
| 700 |
1 |
|
|a Fekih Romdhane, Feten
|4 oth
|
| 700 |
1 |
|
|a Ouertani, Haroun
|4 oth
|
| 700 |
1 |
|
|a Cheour, Majda
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier
|a David, Lauren A. ELSEVIER
|t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
|d 2016
|g Amsterdam [u.a.]
|w (DE-627)ELV024210129
|
| 773 |
1 |
8 |
|g volume:13
|g year:2019
|g number:1
|g pages:57-62
|g extent:6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.pcd.2018.09.003
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 50.70
|j Energie: Allgemeines
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 13
|j 2019
|e 1
|h 57-62
|g 6
|